Company intelligence / Profile preview

Camelot

Florida, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Camelot BioCapital supports early- to mid-stage therapeutics; drug candidates have reached human clinical trials, with prior portfolio companies achieving 7 FDA approvals[1][2].

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeBiologic
Industry: Investors

Partnerships

Massachusetts Institute of TechnologyMayo ClinicMemorial Sloan Kettering Cancer CenterMD AndersonWashington University at St. LouisRutgers UniversityNIH/NCIVeterans Health AdministrationUniversity of MiamiMoffitt Cancer CenterUniversity of FloridaRoswell Park Cancer InstituteHebrew UniversityUniversity of San FranciscoUniversity of PennsylvaniaJohns HopkinsWeizmann InstituteUniversity of AlabamaPittsburgh UniversityPrinceton UniversityOhio State UniversityTechnion Israel Institute of Technology

Beyond the preview

Go deeper on Camelot.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Camelot.

Explore the full profile